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Abstract: Cardiac adverse effects are among the leading causes of the discontinuation of clinical 
trials and the withdrawal of drugs from the market. The novel concept of ‘hidden cardiotoxicity’ is 
defined as cardiotoxicity of a drug that manifests in the diseased (e.g. ischemic/reperfused), but not 
in the healthy heart or as a drug-induced deterioration of cardiac stress adaptation (e.g. ischemic 
conditioning). Here, we aimed to test if the cardiotoxicity of a selective COX-2 inhibitor rofecoxib 
that was revealed during its clinical use, i.e., increased occurrence of proarrhythmic and thrombotic 
events, could have been revealed in early phases of drug development by using preclinical models 
of ischemia/reperfusion (I/R) injury. Rats that were treated with rofecoxib or vehicle for four weeks 
were subjected to 30 min. coronary artery occlusion and 120 min. reperfusion with or without 
cardioprotection that is induced by ischemic preconditioning (IPC). Rofecoxib increased overall the 
arrhythmias including ventricular fibrillation (VF) during I/R. The proarrhythmic effect of 
rofecoxib during I/R was not observed in the IPC group. Rofecoxib prolonged the action potential 
duration (APD) in isolated papillary muscles, which was not seen in the simulated IPC group. 
Interestingly, while showing hidden cardiotoxicity manifested as a proarrhythmic effect during 
I/R, rofecoxib decreased the infarct size and increased the survival of adult rat cardiac myocytes 
that were subjected to simulated I/R injury. This is the first demonstration that rofecoxib increased 
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acute mortality due to its proarrhythmic effect via increased APD during I/R. Rofecoxib did not 
interfere with the cardiprotective effect of IPC; moreover, IPC was able to protect against 
rofecoxib-induced hidden cardiotoxicity. These results show that cardiac safety testing with simple 
preclinical models of I/R injury uncovers hidden cardiotoxicity of rofecoxib and might reveal the 
hidden cardiotoxicity of other drugs. 
Keywords: cardiotoxicity; COX-2; electrophysiology; safety testing; arrhythmia; Vioxx; ischemic 
conditioning; reperfusion injury; hiddentox; pharmacovigilance 
 
1. Introduction 
Unexpected clinical cardiotoxicity is still the leading cause of discontinuation of clinical trials 
and the withdrawal of drugs from the market despite great efforts to detect cardiotoxicity in the 
preclinical phase of drug development programs [1]. Such cardiotoxic effects remain undetected 
during preclinical and early clinical safety studies and they may manifest in the presence of cardiac 
diseases e.g. in myocardial I/R conditions; therefore, we termed this phenomenon “hidden 
cardiotoxicity” [2]. 
Hidden cardiotoxicity often manifests as ischemia-related lethal myocardial injury and/or as 
I/R-induced arrhythmias and/or as cardiac dysfunction. Thus, drugs with hidden cardiotoxic 
properties may present as a serious risk to patients as drugs with overt cardiotoxicity, such as certain 
cancer treatments [3]. The mechanisms of hidden cardiotoxicity may include the activation of cell 
death- or pro-arrhythmic processes during cardiac I/R, as well as the inhibition of cardioprotective 
signaling pathways (e.g. ischemic conditioning-induced protection), either of which may be 
aggravated by the presence of cardiovascular comorbidities [2]. The mechanism of cardiovascular 
toxicity of cancer treatments is described elsewhere in detail. 
Nearly 500 medicinal products were withdrawn from the market between 1953 and 2013 [4], the 
majority of which is related to cardiac adverse events [1]. Moreover, an estimated 197,000 deaths are 
attributed to adverse drug reactions in the European Union each year [5]. 
Hidden cardiotoxicity remains undetected in the preclinical and early clinical phases of drug 
development, since the current guidelines only require the assessment of drug safety in healthy 
animals [6,7]. In addition, preclinical and clinical cardiac electrophysiological safety test guidelines 
advocate the use of healthy animals, tissues, and healthy human volunteers for the assessment of the 
pro-arrhythmic adverse effects of compounds in development and these tests do not represent 
patients with increased arrhythmia susceptibility [8,9]. However, in clinical trials, cardiotoxic 
adverse events occur in an unpredictable manner, often in patients with cardiac diseases and/or with 
cardiovascular comorbidities, e.g., hyperlipidemia, hyperglycemia, hypertension, aging, or 
inflammatory diseases [10,11]. Indeed, the guidelines for the treatment of heart failure by the 
American College of Cardiology Foundation/American Heart Association recommend avoiding the 
use of certain medications in heart failure, e.g., cyclooxygenase-2 (COX-2) inhibitors, since they may 
exacerbate underlying myocardial dysfunction [12]. 
Rofecoxib, which is a COX-2 inhibitor, was withdrawn from the market due to an increased risk 
of cardiovascular prothrombotic events being observed in the VIGOR and APPROVe trials [13,14]. 
Later, in a meta-analysis that included 116,094 participants, it was shown that the use of rofecoxib 
was associated with an increased risk of arrhythmias [15]. Several other mechanism have been 
proposed for rofecoxib-induced cardiotoxicity, such as the inhibition of protection against I/R injury, 
prevention of production of epi-lipoxins, increase in blood pressure, and inhibition of vascular 
remodeling, however, none of those has been detected during preclinical safety assessment [16]. 
Nevertheless, according to our definition, rofecoxib showed hidden cardiotoxic properties; earlier 
and appropriate preclinical tests could have revealed these effects, thus preventing a number of 
serious adverse events, thereby increasing patient safety. The fact that the cardiotoxic effects of 
rofecoxib remained hidden in preclinical studies and was only revealed in phase 4 clinical studies 
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and by a following metaanalysis and the enormous costs of long-term cardiovascular outcome trials 
required to reveal hidden cardiotoxicity suggest that more sensitive screening methods are required 
for toxicity studies including animal models of myocardial I/R and/or comorbidities [17,18]. 
To this end, here we aimed to investigate that hidden cardiotoxicity of rofecoxib, that remained 
unrevealed during preclinical safety assessment, could have been detected before its authorization 
in pathological conditions while using cellular-, isolated tissue-, and small animal models of acute 
I/R injury, and to test the effect of rofecoxib on cardioprotection that is elicited by IPC. Our results 
show that hidden cardiotoxic property of rofecoxib can be revealed with preclinical models of I/R 
injury. Safety testing of other drugs in the presence of I/R might uncover their hidden 
cardiotoxicities. 
2. Materials and Methods 
2.1. Ethical Considerations 
This investigation complies with the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health (NIH publication No. 85–23, revised 1996), to the 
EU Directive (2010/63/EU). The current study is based on the rule of the replacement, refinement, or 
reduction (3Rs). The animal ethics committee of the Semmelweis University, Budapest, Hungary, 
and by the National Scientific Ethical Committee on Animal Experimentation approved it, and it 
was permitted by the government (Food Chain Safety and Animal Health Directorate of the 
Government Office for Pest County (PE/EA/1784-7/2017) and by the Ethical Committee for the 
Protection of Animals in Research of the University of Szeged, Szeged, Hungary (I-74-24-2017), and 
by the Department of Public Health and Food Control of the Government Office for Csongrád 
County, Hungary (XIII/3331/2017). 
2.2. Sources of Chemicals 
Most of the chemicals were purchased from Sigma (St. Louis, MO, US), including 
hydroxyethylcellulose (#09368), Evans blue dye (#E2129), triphenyltetrazolium chloride (#T8877), 
HEPES buffer (#H3375), dimethyl-sulfoxide (DMSO #D5879 or #D2650), 2-Deoxy-D-glucose 
(#D8375), and laminin (#L2020). Other sources: heparin (Merck, Darmstadt, Germany, #375095), 
rofecoxib (MedChemExpress Europe, Sollentuna, Sweden, #HY-17372), pentobarbital (Produlab 
Pharma, Raamsdonksweer, The Netherlands, #17F015), MgSO4 (Reanal, Budapest, Hungary, 
#20341), collagenase II (Biochrom GmbH, Berlin, Germany, #c2-22), fetal bovine serum (FBS, 
EuroClone, Pero MI, Italy, #ECS0180L), M199 (Lonza, Verviers, Belgium, #BE12-117F), Bovine Serum 
Albumin (BSA, Santa Cruz Biotechnology, Santa Cruz CA, USA, #sc-2323), calcein AM (PromoCell 
GmbH, Heidelberg, Germany, #PK-CA707-80011-3), Dulbecco’s Phosphate-Buffered Saline (DPBS, 
Gibco, Grand Island New York, USA, #14080-055). 
2.3. In vivo Ischemia/Reperfusion Injury Study 
For in vivo experiments, male Wistar rats of 187–287 g were treated with 5.12 mg kg−1 rofecoxib 
or with its vehicle, 1% hydroxyethylcellulose by oral gavage once daily for 28 ± 1 days. The dose of 
rofecoxib was extrapolated from the daily human dose (50 mg daily) that showed cardiovascular 
side effects in clinical studies [13] by using the formula that was described by Reagan-Shaw et al. 
[19]: HED ሺmg × kgିଵሻ = Animal dose ሺmg × kgିଵሻ ×  rat 𝐾௠human 𝐾௠ (1) 
Animal dose was calculated by dividing the HED (human equivalent dose, 50 mg 60 kg−1 for 
average 60 kg adult) by the ratio of average rat correction factor (rat Km = 6) and the average human 
correction factor (human Km = 37). 
The animals were housed in a temperature (22 ± 2 °C)-, and humidity-controlled room at a 12 h 
light/dark cycle and had free access to laboratory chow and drinking water ad libitum. Groups of 
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animals treated with rofecoxib or vehicle for 28 ± 1 days and weighing 320–440 g were anaesthetized 
with 60 mg kg−1 pentobarbital intraperitoneally. The absence of pedal reflex was considered as being 
deep surgical anesthesia. Body surface electrocardiogram (ECG) was monitored throughout the 
experiments by using standard limb leads (AD Instruments, Bella Vista, Australia). Cannulated right 
carotid artery was used for the measurement of mean arterial blood pressure (MAP, AD 
Instruments, Bella Vista, Australia) and fluid supplementation with saline containing 10 IU kg−1 
heparin. The core body temperature was maintained at physiological temperature with a heating 
pad (Harvard Apparatus, Holliston, Massachusetts). Rats were ventilated with rodent ventilator 
(Ugo-Basile, Gemonio, Italy) with room air in a volume of 6.2 mL kg−1 and frequency of 69 ± 3 breath 
min.−1. A 5-0 Prolene suture (Ethicon, Johnson & Johnson, Budapest, Hungary) was looped around 
the left anterior descending (LAD) coronary artery [20]. After the previously listed procedures the 0 
min. of experiment was appointed. The animals received intraperitoneal injection of 100 IU kg−1 
heparin at 35, 65, and 185 min. of experiments. 
Experimental design and study protocols are illustrated in Figure 1. Altogether 62 animals were 
included in the in vivo experiments. In order to achieve comparable number of surviving animals in 
each group, based on our preliminary observations 30% more animals were assigned to the 
rofecoxib-treated group (n = 35) than to the vehicle-treated group (n = 27). Rofecoxib- and 
vehicle-treated animals were then subjected to I/R with or without IPC using directed 
randomization during the study to assign more animals to the higher mortality groups: I/R+vehicle 
group (n = 11), I/R + rofecoxib group (n = 18), IPC+vehicle group (n = 16) and IPC+rofecoxib group (n 
= 17). I/R was induced by 30 min. LAD occlusion and IPC was elicited by 3 cycles of brief 5-min. LAD 
occlusion and 5 min. reperfusion before I/R. Animals received a 120 min. reperfusion. Appearance of 
ischemia was confirmed by ST segment elevation or depression, appearance of arrhythmias and 
pallor of the myocardial regions distal to the site of occlusion. 
 
Figure 1. In vivo ischemia/reperfusion (I/R) injury study protocol: male Wistar rats treated with 
rofecoxib (5.12 mg kg−1/day) or vehicle for 4 weeks were subjected to I/R of the left anterior 
descending (LAD) coronary artery or to ischemic preconditioning (IPC) elicited by three cycles of 5 
min. LAD occlusion and 5 min. reperfusion before the index ischemia. 
2.3.1. Mortality Analysis 
The cause of death was classified as either irreversible VF, pulseless electrical activity, and 
bradycardia (<150 BPM), accompanied by hypotension (MAP < 15 mmHg). 
2.3.2. Arrhythmia Analysis 
The incidence and duration of arrhythmias occurring during 30 min. of ischemia and the first 15 
min. of reperfusion were analyzed by two investigators independently in a blinded fashion 
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according to the Lambeth conventions and quantified while using the “score A” described by Curtis 
and Walker [21,22]. The 45 min-long ECG records were divided into five-minute periods, and then 
each interval was scored according to most severe arrhythmia type in the given interval. In the case 
of fatal VF, scores were kept throughout the subsequent periods. The arrhythmia maps were 
constructed by using a color scale, where the 5-min. periods were colored according to the most 
severe arrhythmia type. 
2.3.3. Infarct Size Measurement 
After 120 min. of reperfusion hearts were excised and perfused for 2 min. with oxygenated 
Krebs-Henseleit solution (in mM: NaCl 118, KCl 4.7, MgSO4 1.2, CaCl2 1.25, KH2PO4 1.2, NaHCO3 25, 
and glucose 11) at 37 °C in Langendorff mode to remove blood from the tissue, LAD was 
re-occluded, and the area at risk (AAR) was negatively stained with Evans blue dye through the 
ascending aorta. For the assessment of viable myocardial tissue, 2 mm-thick slices were cut and 
incubated in 1% triphenyltetrazolium chloride at 37 °C for 14 min. The slices were weighed and 
scanned. Planimetric analyses were performed by two independent, blinded investigators with 
InfarctSize 2.4b software (Pharmahungary Group, Budapest, Hungary). Area at risk (AAR) was 
expressed as the proportion of the left ventricular area, and the infarct size as the proportion of the 
AAR, and then areas were normalized to the mass of each slice. 
2.4. Ex vivo Simulated Ischemia/Reperfusion Injury Study 
For isolated papillary muscle experiments, male Wistar rats weighing 200–250 g were used. The 
rats were anesthetized with pentobarbital intraperitoneally (30 mg kg−1), followed by rapid excision 
of the heart via thoracotomy. Left ventricular papillary muscle preparations were mounted in a 
tissue chamber (volume together with solution reservoir: 50 mL) and they were then continuously 
perfused with oxygen–saturated, HEPES-buffered Tyrode’s solution (in mM: NaCl 144, NaH2PO4 
0.4, KCl 4, MgSO4 0.53, CaCl2 1.8, glucose 5.5, HEPES 5 at pH 7.4, 37 °C). The preparations were 
stimulated (Hugo Sachs Electronik stimulator type 215/II, March-Hugstetten, Germany) at a cycle 
length of 1000 ms (frequency: 1 Hz), while using 2 ms-long rectangular constant voltage pulses that 
were isolated from ground and delivered across bipolar platinum electrodes in contact with the 
preparation. Transmembrane potentials were recorded while using the conventional microelectrode 
technique. Microelectrodes that were filled with 3 M KCl and exhibiting tip resistances of 5–20 MΩ 
were connected to a high impedance electrometer (type 309, MDE Heidelberg GMBH, Heidelberg, 
Germany) coupled to a dual beam oscilloscope (Tektronix, Beaverton, OR, USA). 
Figure 2 illustrates the experimental design and study protocols. Altogether, 54 animals were 
included in the ex vivo experiments. Papillary muscles of 6 animals/group were superfused with 
oxygen–saturated HEPES-buffered Tyrode’s solution (normoxic solution) and were allowed to 
equilibrate for 60 min. before baseline measurements were taken. Throughout the experiments, 
measurements were taken every 2 min. Following the 60-min. equilibration period, groups of 
preparations were superfused with normoxic solution containing either vehicle, 1 or 10 µM 
rofecoxib (Normoxia groups) dissolved in DMSO for 90 min. The concentration of 1 µM was chosen 
for rofecoxib based on the peak plasma concentration (Cmax) measured after a single, 5 mg kg−1 oral 
dose of rofecoxib in rats [23]. The highest final concentration of DMSO following the application of 
10 µM rofecoxib was 0.2% in the solution. Following the 60-min. baseline superfusion, groups of 
preparations were superfused with normoxic solution for 30 min. then with nitrogen-saturated and 
HEPES-buffered solution (ischemic solution, in mM: NaCl 144, NaH2PO4 0.4, KCl 4, MgSO4 0.53, 
CaCl2 1.8, 2-deoxy-D-glucose 5.5, HEPES 5 at pH 6.9, and 37 °C) for 30 min., and then with normoxic 
solution for 30 min., all containing either vehicle, 1 or 10 µM rofecoxib (sI/R groups) to induce 
simulated I/R (sI/R). In additional groups of preparations, sIPC (sIPC groups) was performed before 
30 min. ischemia by using the following protocol: three times 5-min. simulated ischemia with 
intermittent 5 min. reperfusion periods. Before index ischemia, the last reperfusion lasted 15 min. 
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Figure 2. Ex vivo simulated ischemia/reperfusion (sI/R) injury study protocol: action potential 
parameters were measured in isolated rat left ventricular papillary muscles in normoxic, sI/R and 
simulated ischemic preconditioning (sIPC) conditions in the presence of vehicle or 1 or 10 µM 
rofecoxib, respectively. 
Evaluation of Action Potential Parameters 
Unbiased evaluation of action potential parameters was achieved by automatic evaluation 
while using software that was developed in Department of Pharmacology and Pharmacotherapy, 
University of Szeged (Hugo Sachs Electronic-Action Potential Evaluation System): Vmax, CT, RMP, 
APA, APD at 75 and 90% of repolarization (APD75 and APD90, respectively). The maintenance of the 
same impalement throughout each experiment was attempted. However, in case an impalement was 
dislodged, electrode adjustment was performed, and the experiment was terminated and all data 
were excluded from analysis if the action potential characteristics of the re-established impalement 
deviated by more than 5% from the previous measurement. 
2.5. In vitro Simulated Ischemia/Reperfusion Injury Study 
For in vitro cell culture experiments, male Wistar rats weighing 150–200 g were used. The rats 
were anesthetized with pentobarbital intraperitoneally (60 mg kg−1) and each animal was 
heparinized (500 IU/kg) through femoral vein. The hearts were excised, cannulated, and perfused 
retrograde with Krebs–Henseleit solution to wash out the blood. Then hearts were perfused with 
collagenase II (8000 U/mL) containing Krebs solution for 30–45 min. Subsequently, the ventricles 
were removed and then chopped in small pieces and digestion continued for more 10 min. The cell 
suspension was filtrated and pelleted under gravity, repeated 2–3 times. Under these steps, the Ca2+ 
concentration was gradually increased up to a final of 1 mM. The isolated cells (7500 cell/well) were 
plated in laminin-coated wells of a 24-well plate (Thermo Fisher Scientific, Waltham, USA) and 
incubated for 3 h in proliferation media (5% FBS containing M199) and in growth media (serum free 
M199) for 24 h. The experimental design and study protocols are illustrated on Figure 3. Altogether 
12 animals were included in the in vitro experiments. To achieve the n = 6 group size in all the 
different normoxic and sI/R groups, i.e. six separate series of cell isolation procedures were made 
using two hearts, one for the normoxic and one for the sI/R groups. After 24 h, growth media was 
replaced with growth media containing vehicle or rofecoxib in increasing doses (0.1, 0.3, 1, 3, and 10 
µM) and the cells were kept in CO2 incubator (Scancell - Labogene, Lynge, Denmark) for 60 min. 
[24]. After 60 min. in groups of cells, growth media was replaced for 180 min. with either normoxic 
solution (in mM: NaCl 125, KCl 5.4, NaH2PO4 1.2, MgCl2 0.5, HEPES 20, MgSO4, 1.3, CaCl2 1, glucose 
15, taurine 5, creatine-monohydrate 2.5 and BSA 0.1%, pH 7.4) in CO2 incubator (Normoxia groups) 
or with hypoxic solution (in mM: NaCl 119, KCl 5.4, MgSO4 1.3, NaH2PO4 1.2, HEPES 5, MgCl2 0.5, 
CaCl2 0.9, Na-lactate 20, BSA 0.1% pH 6.4) in a three-gas (95% N2 and 5% CO2) incubator (sI/R 
groups, Panasonic Healthcare Co., Ltd., Gunma, Japan), both containing the fore-mentioned doses of 
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rofecoxib or vehicle only [25]. Following the 180 min. normoxic or sI/R conditions cells were kept in 
growth medium containing vehicle or rofecoxib in increasing doses in CO2 incubator. 
 
Figure 3. In vitro simulated ischemia/reperfusion (sI/R) injury study protocol: cell viability of 
cultured isolated cardiac myocytes was measured in normoxic and sI/R conditions in the presence of 
vehicle, 0.1, 0.3, 1, 3, or 10 µM rofecoxib, respectively. 
Viability Assay 
Calcein staining was performed to assess cell viability [26]. The cells were washed with warm 
DPBS and calcein solution (1 µM) was added and incubated for 30 min. at room temperature in a 
dark chamber. Afterwards, the calcein solution was replaced with fresh DPBS. An unbiased 
evaluation was performed by automatic detection of the fluorescence intensity of each well by 
Varioskan Lux multimode microplate reader (Thermo Fisher Scientific, Waltham, USA) at 
temperature: 37 °C; excitation wavelength: 490nm; emission wavelength: 520 nm. Autofluorescence 
of rofecoxib that was measured in DPBS (0.1, 0.3, 1, 3 and 10 µM) was not detected; therefore, 
interference did not influence the results of the viability assay. Six separate technical repeats were 
performed, and an average of four wells/group/repeats are presented on the graph. The cell survival 
data are expressed as relative fluorescence units (RFU). Normoxia + vehicle group was set to 1 RFU 
arbitrary unit and all data were normalized to the averaged sI/R group. 
2.6. Statistical Analysis 
The Odds Ratio (OR) with 95% confidence interval (CI 95%) was estimated by logistic 
regression to identify the mortality rate differences among the treatment groups. Continuous data 
are shown as mean ± standard error. The difference between treatment groups was evaluated while 
using two-way ANOVA or one-way ANOVA followed by Fisher LSD post hoc tests with multiple 
comparisons (for in vivo infarct size analysis, for ex vivo action potential measurements, and for in 
vitro cell viability study) and two-way repeated measures ANOVA, followed by Fisher LSD post 
hoc test (for in vivo arrhythmia analysis). We used GraphPad Prism (version 6.0, GraphPad 
Software, California, USA) and R (version 3.4) with the lme4 library. We claimed that the differences 
were statistically significant if p < 0.05. 
3. Results 
3.1. Chronic Rofecoxib Treatment Increased Acute Mortality During Cardiac Ischemia/Reperfusion 
The rats were treated with rofecoxib for four weeks and then subjected to 30 min. ischemia and 
120 min. reperfusion to investigate hidden cardiotoxicity of rofecoxib. Rofecoxib treatment increased 
the mortality rate as compared to the pooled data of other groups (OR = 7.73, CI 95% = 1.70–34.97 vs. 
I/R + vehicle + IPC+vehicle + IPC+rofecoxib; p < 0.008; Figure 4). In the I/R+rofecoxib group, seven 
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animals died due to irreversible VF during the ischemic period and one animal died due to a sudden 
drop in blood pressure during reperfusion. In the I/R + vehicle group, only one animal died due to 
irreversible VF during the ischemic period. Animals died during the short I/R stimuli of IPC 
(six/each IPC group) were excluded from further evaluations and are not shown in Figures 3,4, and 
5. In the IPC + rofecoxib group, one animal died due sudden drop in blood pressure in the 
reperfusion period. 
 
Figure 4. Rofecoxib treatment increased the mortality rate in the ischemia/reperfusion (I/R) group in 
vivo. When compared to the pooled data of other groups, the mortality-increasing effect of rofecoxib 
was significant (OR = 7.73, CI 95% = 1.70–34.97, p < 0.008). IPC: ischemic preconditioning. 
3.2. Chronic Rofecoxib Treatment Increased Arrhythmia Score in Cardiac Ischemia/Reperfusion 
The severity and duration of arrhythmias were evaluated by scoring 5 min. intervals according 
to the Lambeth conventions during cardiac ischemia and early reperfusion. The results are 
represented as an arrhythmia map in Figure 5, showing the type of most severe arrhythmias 
occurring during a given 5-min. interval by a color scale. 
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Figure 5. Arrhythmia maps showing the arrhythmias in the order of severity during 30 min. ischemia 
and at the first 15 min. of reperfusion. Each row represents arrhythmias of each animal. The different 
color boxes show 5 min. periods. The animals died during the IPC (ischemic preconditioning) are not 
shown. In the I/R + rofecoxib group animals 1–7 died due to ventricular fibrillation (red and black 
box). 
The peak arrhythmia scores were achieved in the I/R + vehicle groups after 10 min. of ischemia 
(50th min. of experiment) and, following that, they rapidly decreased (Figure 6). In contrast, in the I/R 
+ rofecoxib group the initial increase runs parallel with the I/R + vehicle group, but, following that, 
the decline is much slower. We tested the statistical hypothesis that scores decrease in parallel by 
fitting the linear mixed regression model on the observations by excluding the data of the first 
period. The difference between slopes was highly significant (p Time x Group interaction = 0.00681), thus 
suggesting a pronounced effect of rofecoxib on the recovery. Yet, such a difference does not exist 
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between the estimated peak values at the end of 50th minute of experiment (p = 0.66367). The initial 
increase of arrhythmia scores was not observed in the IPC groups. 
 
Figure 6. Arrhythmia scores declined gradually starting from the 50th min. in the I/R+vehicle 
(ischemia/reperfusion) group but remained elevated in the I/R + rofecoxib group (*p < 0.05 I/R + 
vehicle vs. I/R + rofecoxib, n = 11–18). IPC (ischemic preconditioning) prevented initial increase of 
arrhythmia score (#p < 0.05 IPC + rofecoxib vs. I/R + rofecoxib, ∆p < 0.05 IPC + vehicle vs. I/R + 
rofecoxib, n = 10–11). 
3.3. Rofecoxib Decreased Infarct Size and did not Interfere with Cardioprotection by Ischemic Preconditioning 
We measured infarct size to explore the effect of rofecoxib on I/R injury and cardioprotection by 
IPC. Rofecoxib reduced infarct size (I/R + rofecoxib) as compared to the vehicle-treated (I/R + 
vehicle) group (Figure 7). Infarct size was significantly smaller in the IPC+vehicle group as 
compared to I/R+vehicle. Chronic rofecoxib treatment did not affect infarct size-limiting effect of IPC 
in IPC+rofecoxib when compared to the IPC+vehicle group. 
 
Figure 7. Chronic rofecoxib treatment reduced infarct size and did not interfere with 
cardioprotection by ischemic preconditioning. (*p < 0.05 vs. I/R + vehicle, #p < 0.05 vs. I/R + rofecoxib, 
n = 9–10). 
No significant difference was observed between groups for the AAR expressed as a percentage 
of the left ventricle (I/R + vehicle: 51.1 ± 2.8%; IPC + vehicle: 41.6 ± 2.3%; I/R + rofecoxib: 44.8 ± 4.1%; 
IPC+rofecoxib 50.6 ± 4.9%). 
3.4. Rofecoxib Increased the Action Potential Duration in Rat Isolated Papillary Muscles at the end of 
Simulated Ischemia/Reperfusion and this Effect was not Observed Ischemic Preconditioning Groups 
In vitro simulated ischemia/reperfusion (sI/R) and sIPC experiments were performed on 
isolated rat left ventricular papillary muscles in order to analyze the effect of rofecoxib on cardiac 
action potential parameters. Rofecoxib treatment did not change any of the investigated 
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electrophysiological parameters, including APD90 (Figure 8A,B) and APD75 (Figure S1A,B) in 
normoxic conditions. As expected, the 30 min. simulated ischemia significantly shortened APD90 
(Figure 8A) and APD75 (Figure S1A) in all groups that were subjected to ischemia when compared to 
the respective normoxic groups. However, importantly, in the presence of sI/R rofecoxib 
dose-dependently increased APD90 (Figure 8B) and increased APD75 (Figure S1B) upon reperfusion 
following the 30 min. simulated ischemia. In the sIPC group, these effects of rofecoxib on APD were 
not seen during reperfusion (Figure 8B and Figure S1B). The effects of rofecoxib on action potential 
amplitude (APA), conduction time (CT), resting membrane potential (RMP), and maximum rate of 
depolarization (Vmax) in sI/R are detailed in Table S1. Simulated ischemia (30 min.) resulted in an 
increase of CT in all groups, while Vmax was significantly reduced in the rofecoxib treated groups 
(Table S1), possibly indicating decreased sodium channel function following rofecoxib 
administration in ischemic conditions only. 
 
Figure 8. (A) Action potential duration at 90% repolarization (APD90) decreased by the end of 30 min. 
simulated ischemia in the simulated ischemia/reperfusion groups (sI/R) and simulated ischemic 
preconditioning groups (sIPC) as compared to the normoxia (N) group. (B) Rofecoxib increased the 
APD90 in adult rat isolated papillary muscles at the end of reperfusion and this effect was reversed by 
sIPC (*p < 0.05 vs. corresponding normoxia group, #p < 0.05 vs. sI/R + vehicle,†p < 0.05 vs. sI/R + 1 µM 
rofecoxib, ∆p < 0.05 vs. corresponding sI/R group, n = 5–6). 
3.5. Rofecoxib Treatment Increased Viability of Isolated Adult Rat Cardiac Myocytes in Normoxia and in 
Simulated Ischemia/Reperfusion Injury 
In vitro sI/R experiments were performed in order to analyze the effect of rofecoxib on viability 
of isolated cardiac myocytes. sI/R caused significant cell death (Figure 9) as compared to normoxic 
control, which was reversed by rofecoxib treatment at 0.1, 0.3, 1, and 3 µM concentration, 
respectively, thereby supporting the in vivo data showing the infarct size reduction by rofecoxib 
(Figure 7). 
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Figure 9. Rofecoxib increased cell viability in isolated rat cardiac myocytes exposed to simulated 
ischemia/reperfusion (sI/R). Normoxia (N) + vehicle group was set to 1 relative fluorescence units 
(RFU) arbitrary unit and all of the data were normalized to the averaged sI/R group (*p < 0.05 vs. 
Normoxia+vehicle, #p < 0.05 vs. sI/R + vehicle, n = 6). RFU-arbitrary unit: Relative fluorescence unit. 
4. Discussion 
Here, we demonstrated, for the first time, in the literature that rofecoxib increased acute 
mortality due to its proarrhythmic effect via increased APD during I/R. We also showed that 
rofecoxib did not interfere with the cardiprotective effect of IPC and that IPC was able to protect 
against rofecoxib-induced hidden cardiotoxicity. 
In the present study, we have shown that chronic rofecoxib treatment increased mortality after 
acute cardiac I/R in rats. Increased mortality due to rofecoxib have also been reported in clinical 
trials. Gislason et al. concluded that selective COX-2 inhibition with rofecoxib and celecoxib 
increased the mortality at all doses in patients with prior myocardial infarction; however, the 
underlying mechanisms were not studied [27]. Our present data imply that the increased mortality 
due to rofecoxib treatment can be attributed to its proarrhythmic property that only manifests 
following I/R. Myocardial ischemia per se renders myocardial tissue more susceptible to ventricular 
arrhythmias and I/R injury may exacerbate proarrhythmic effects of drugs [2]. To further analyze the 
hidden cardiotoxic effects of rofecoxib, we subjected left ventricular papillary muscles to sI/R. 
Rofecoxib did not change the action potential parameters in normoxic conditions; however, 
following sI/R, several, potentially proarrhythmic effects appeared. First, the APD was only 
significantly prolonged by rofecoxib in cardiac tissue that were subjected to sI/R. Increased spatial 
dispersion of repolarization between normoxic and ischemic myocardium is a critically important 
factor that promotes the development of ischemia-induced arrhythmias [28,29]. Based on the present 
results, rofecoxib might further exacerbate the differences in APD between normoxic and ischemic 
myocardium, further increasing the arrhythmia substrate in I/R. Secondly, simulated ischemia in the 
presence of rofecoxib more markedly reduced action potential upstroke (characterized by decreased 
Vmax) by the end of test ischemia, which only suggested an additional reduction of sodium channel 
function by rofecoxib in sI/R conditions, further decreasing the already slowed impulse conduction 
in depolarized ischemic myocardial tissue [30]. 
These data suggest that adverse effects of COX-2 inhibitors may occur only in the presence of 
cardiac I/R. Our present results are in line with clinical data, as a comprehensive meta-analysis of 114 
randomized trials reported increased arrhythmia risks in rofecoxib-treated patients and found that a 
time-cumulative meta-analytic approach would have revealed its cardiotoxicity earlier [15]. 
However, a subgroup analysis of patients with ischemic heart diseases was not performed in this 
meta-analysis, which might have revealed its cardiotoxicity even earlier. These results clearly show 
that the exclusion of patients with preexisting cardiovascular diseases from clinical studies and the 
lack of subgroup analyses on patients with underlying co-morbidities in clinical trials may lead to 
the loss of valuable safety information on drugs with potential hidden cardiotoxic effects [2,31]. Our 
current preclinical results are in line with previous clinical data. Although the repeated 
administration of valdecoxib had no effect on QTc interval duration in healthy volunteers [32], and 
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valdecoxib and parecoxib did not increase the risk for cardiac adverse events in patients recovering 
from major noncardiac surgical procedures [33], but the use of valdecoxib and parecoxib in patients 
that were subjected to coronary-artery bypass grafting (CABG) was associated with an increased 
incidence of cardiovascular events [34]. However, in the latter studies, the incidence of arrhythmias 
was not evaluated. Furthermore, mortality was increased by celecoxib in a chronic post-myocardial 
infarction-induced heart failure in pigs due to left ventricular rupture and cardiac decompensation 
[35]. 
Here we also investigated the interaction of rofecoxib with IPC since the hidden cardiotoxic 
effect of drugs mightb manifest not only as aggravation of I/R injury, but also as attenuation of 
ischemic adaptation of the myocardium by ischemic conditioning [2]. We found that rofecoxib alone 
decreased infarct size and did not interfere with the protective effect of IPC. We tested the 
cytoprotective effect of rofecoxib in cardiac myocytes subjected to sI/R and found an increased cell 
survival due to rofecoxib treatment to further test whether the infarct size limiting effect was due to 
direct cardio-cytoprotective effect or was an artefact due to the significantly less survival of animals 
with larger infarct size. These results show that rofecoxib has a direct cardio-cytoprotective effect. 
An infarct size-limiting effect was also shown in rats while using another COX-2 inhibitor celecoxib. 
Furthermore, in this study mortality rate of celecoxib treatment was not reported, which can also 
significantly alter the outcomes of cardioprotection [20]. DFU, a compound that is structurally 
related to rofecoxib, led to a significant improvement in left ventricular end-diastolic pressure and 
LV systolic pressure and a reduction in infarct size after myocardial infarction in Lewis male rats 
[36]. A neutral effect on infarct size was shown in different animal models of myocardial infarction 
with the use of various COX-2 inhibitors [37–40]. In contrast, Inserte et al. showed that in transgenic 
mice constitutively expressing human COX-2 in cardiomyocytes functional recovery was improved, 
cell death was reduced after 40 min. of ex vivo ischemia, and that pretreatment of mice with the 
COX-2 inhibitor DFU attenuated cardioprotection [41]. In a recent publication, inducible 
cardiac-specific COX-2 overexpression showed a infarct-limiting effect in mice [42]. These results 
suggest that the presence and/or extent of cardioprotection by COX-2 inhibitors may vary due to 
both the nature of the applied inhibitor and the model species according to different anatomy, 
physiology, and pharmacokinetics, dosing, etc., and due to differences in surgery protocols 
(anesthetics, co-medications, chronic, or acute cardiac ischemia etc.). Confirming our finding on 
direct cardioprotection by rofecoxib in vivo, here we also showed that rofecoxib increased cell 
survival in sI/R on the isolated cardiomyocytes. These findings are in line with a previous report, 
where the cytoprotective effects of COX-2 inhibition was demonstrated in H9c2 cells and primary rat 
cardiomyocytes in a simulated hypoxia/reoxygenation (H/R) model, showing that a pretreatment 
with NS-398 significantly attenuated H/R-induced cellular injury [43]. Therefore, a Janus-like nature 
of COX-2 inhibition on cardioprotection seems plausible. Here, we found that rofecoxib 
pretreatment did not affect the infarct size limiting effect of IPC. Confirming our results, parecoxib 
administered intravenously 15 min. prior to IPC did not affect the infarct size limiting effect of IPC in 
male Wistar rats [44]. Somewhat in contrast, the protective effect of late phase of ischemic 
conditioning was attributed to the increased expression and activity of COX-2 [45,46]. Similarly, Sato 
et al. showed an upregulation of COX-2 expression in Harlan Sprague Dawley rats in the 
ischemic-reperfused cardiac region by late preconditioning, but not by postconditioning and the use 
of celecoxib completely abrogated the infarct-sparing effect of the combination of two interventions 
[47]. In summary, it is unlikely that a class effect of COX-2 inhibitors regarding their influence on 
cardioprotection by ischemic conditioning exist. Moreover, it should be emphasized that, in our 
present study, the action potential-prolonging effect of rofecoxib in papillary muscle preparations 
subjected to sI/R was not observed when sIPC was applied. These results show that the hidden 
cardiotoxic effects of rofecoxibcan be prevented by ischemic conditioning. Similarly, Maulik et al. 
showed that sIPC protected primary adult rat cardiomyocytes against the direct cardiotoxic effect of 
doxorubicin [48]. However, so far, there are no clinical data on the potential protective effect of IPC 
on drug-induced cardiotoxicity. The currently ongoing (or still unpublished) ERIC-ONC trial aimed 
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to demonstrate whether remote ischemic preconditioning (RIC) reduces subclinical myocardial 
injury due to anthracycline chemotherapy [49]. 
5. Conclusions 
In conclusion, this is the first demonstration that the hidden cardiotoxicity of rofecoxib can be 
revealed by preclinical cardiotoxicity testing while using experimental I/R models. Moreover, IPC 
might protect against the hidden cardiotoxic effects of rofecoxib in vitro. These results show that 
cardiac safety testing with simple preclinical models of I/R injury uncovers the hidden cardiotoxicity 
of rofecoxib and might reveal hidden cardiotoxicity of other drugs. 
6. Limitations 
Our goal to show that hidden cardiotoxicity of rofecoxib can be revealed in a preclinical model 
of I/R injury has been achieved by showing its proarrhythmic properties occurred during its clinical 
use. A limitation of the study is that we did not assess the molecular mechanism of 
rofecoxib-induced prolongation of action potential, arrhythmias, and cardioprotection. The 
proarrhythmic effect of rofecoxib in I/R conditions might be attributed to reduced function of 
sodium channels; however, this was not evaluated in this study mechanistically. 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Table S1: Action 
potential parameters measured in rat papillary muscles in normoxic, simulated ischemia/reperfusion (sI/R) and 
simulated ischemic preconditioning (sIPC) conditions, Figure S1: (A) APD75 decreased by the end of 30 min. 
simulated ischemia in the simulated ischemia/reperfusion groups (sI/R) and simulated ischemic 
preconditioning groups (sIPC). (B) Rofecoxib increased the action potential duration at 75% repolarization 
(APD75) in adult rat isolated papillary muscles at the end of reperfusion and this effect was reversed by sIPC  
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